119 related articles for article (PubMed ID: 37898250)
21. Combined analysis of
Cui L; Gao C; Wang CJ; Zhao XX; Li WJ; Li ZG; Zheng HY; Wang TY; Zhang RD
Leuk Lymphoma; 2021 Feb; 62(2):410-418. PubMed ID: 33054468
[TBL] [Abstract][Full Text] [Related]
22. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
24. GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Madzio J; Pastorczak A; Sedek L; Braun M; Taha J; Wypyszczak K; Trelinska J; Lejman M; Muszynska-Roslan K; Tomasik B; Derwich K; Koltan A; Kazanowska B; Irga-Jaworska N; Badowska W; Matysiak M; Kowalczyk J; Styczynski J; Fendler W; Szczepanski T; Mlynarski W
Genes Chromosomes Cancer; 2019 Sep; 58(9):619-626. PubMed ID: 30859636
[TBL] [Abstract][Full Text] [Related]
25. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
[TBL] [Abstract][Full Text] [Related]
26. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB
Pediatr Blood Cancer; 2019 Aug; 66(8):e27765. PubMed ID: 31012549
[TBL] [Abstract][Full Text] [Related]
27. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
Velasco-Hernandez T; Zanetti SR; Roca-Ho H; Gutierrez-Aguera F; Petazzi P; Sánchez-Martínez D; Molina O; Baroni ML; Fuster JL; Ballerini P; Bueno C; Fernandez-Fuentes N; Engel P; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788237
[TBL] [Abstract][Full Text] [Related]
28. Characterization of CRLF2 Expression in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
Rasekh EO; Atef AM; Khalil M; Ebeid E; Madney Y; Hamdy N
Clin Lab; 2021 Jan; 67(1):. PubMed ID: 33491417
[TBL] [Abstract][Full Text] [Related]
29. Prognostic relevance of surface expression of cytokine receptor-like factor 2 in pediatric B-lineage acute lymphoblastic leukemia.
Singh J; Benjamin M; Pandey AK; Kumari S; Ali MS; Palanichamy JK; Bakhshi S; Singh A; Pushpam D; Kumar A; Seth R; Singh I; Tanwar P; Singh AR; Sharma G; Arora M; Chopra A
Am J Cancer Res; 2023; 13(6):2452-2470. PubMed ID: 37424808
[TBL] [Abstract][Full Text] [Related]
30. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
Virk H; Rana S; Sharma P; Bose PL; Yadav DD; Sachdeva MUS; Varma N; Trehan A; Lad D; Khadwal AR; Malhotra P; Sreedharanunni S
Ann Hematol; 2021 Aug; 100(8):2031-2041. PubMed ID: 34159401
[TBL] [Abstract][Full Text] [Related]
31. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of CRLF2 overexpression and JAK2 mutation in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.
Hassan NM; Abdellateif MS; Radwan EM; Hameed SA; Desouky EDE; Kamel MM; Gameel AM
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e376-e385. PubMed ID: 34987014
[TBL] [Abstract][Full Text] [Related]
33. [Down syndrome and acute lymphoblastic leukemia].
Okamoto Y
Rinsho Ketsueki; 2021; 62(10):1465-1473. PubMed ID: 34732618
[TBL] [Abstract][Full Text] [Related]
34. Philadelphia-like acute lymphoblastic leukemia: Characterization in a pediatric cohort in a referral center in Colombia.
Linares Ballesteros A; Yunis LK; García J; Aponte N; Flechas J; Martinez C; Uribe G; Quintero E; Díaz A; Pardo C; Sarmiento IC; Contreras A; Yunis JJ
Cancer Rep (Hoboken); 2022 May; 5(5):e1587. PubMed ID: 34787376
[TBL] [Abstract][Full Text] [Related]
35. CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia.
Maciel ALT; Wolch K; Emerenciano M; Mansur MB
Genes Chromosomes Cancer; 2022 Jul; 61(7):437-442. PubMed ID: 35253299
[TBL] [Abstract][Full Text] [Related]
36. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.
Palmi C; Vendramini E; Silvestri D; Longinotti G; Frison D; Cario G; Shochat C; Stanulla M; Rossi V; Di Meglio AM; Villa T; Giarin E; Fazio G; Leszl A; Schrappe M; Basso G; Biondi A; Izraeli S; Conter V; Valsecchi MG; Cazzaniga G; Te Kronnie G
Leukemia; 2012 Oct; 26(10):2245-53. PubMed ID: 22484421
[TBL] [Abstract][Full Text] [Related]
37. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Harvey RC; Mullighan CG; Chen IM; Wharton W; Mikhail FM; Carroll AJ; Kang H; Liu W; Dobbin KK; Smith MA; Carroll WL; Devidas M; Bowman WP; Camitta BM; Reaman GH; Hunger SP; Downing JR; Willman CL
Blood; 2010 Jul; 115(26):5312-21. PubMed ID: 20139093
[TBL] [Abstract][Full Text] [Related]
38. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.
Asai D; Imamura T; Suenobu S; Saito A; Hasegawa D; Deguchi T; Hashii Y; Matsumoto K; Kawasaki H; Hori H; Iguchi A; Kosaka Y; Kato K; Horibe K; Yumura-Yagi K; Hara J; Oda M;
Cancer Med; 2013 Jun; 2(3):412-9. PubMed ID: 23930217
[TBL] [Abstract][Full Text] [Related]
39. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.
Cario G; Zimmermann M; Romey R; Gesk S; Vater I; Harbott J; Schrauder A; Moericke A; Izraeli S; Akasaka T; Dyer MJ; Siebert R; Schrappe M; Stanulla M
Blood; 2010 Jul; 115(26):5393-7. PubMed ID: 20378752
[TBL] [Abstract][Full Text] [Related]
40. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.
Ge Z; Gu Y; Zhao G; Li J; Chen B; Han Q; Guo X; Liu J; Li H; Yu MD; Olson J; Steffens S; Payne KJ; Song C; Dovat S
Oncotarget; 2016 Aug; 7(31):49722-49732. PubMed ID: 27391346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
